PDF Archive search engine
Last database update: 25 September at 17:59 - Around 220000 files indexed.
Results for «metastatic»:
Total: 70 results - 0.056 seconds
cvfile 0023229 100%
PALLIATIVE CARE THE KOREAN SOCIETY OF HEMATOLOGY KOREAN CANCER STUDY GROUP KOREAN ASSOCIATION FOR CLINICAL ONCOLOGY CLINICAL TRIAL EXPERIENCE - A Phase III, randomized, Double-blind, Placebo-Controlled, Multicenter study to evaluate the efficacy and safety of Bevacizumab, and Associcated Biomarkers, in combination with Paclitaxel compared with Paclitaxel plus Placebo as 1st line Treatment of patients with HER2-Negative Metastatic Breast cancer, sponsored by Roche, 2013, Principal investigator [GO25632] - A Multi-national Phase III Clinical Study Comparing NK105 Versus Paclitaxel in Patients with Metastatic or Recurrent Breast Cancer, sponsored by Nippon Kayaku, 2013, Principal investigator [NK105] - A Phase 3 Open-label, Randomized, Multicenter study of NKTR-102 versus Treatment of physician’s choice(TPC) in patients with locally recurrent or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine, sponsored by Nektar, 2013, sub-investigator [BEACON] - A Phase 2 Randomized Trial of the Combination of Ridaforolimus and Exmestane, Compared to Ridaforolimus, Dalotuzumab and Exmestane in High Proliferation Estrogen Receptor Positive Breast Cancer Patients.
2012;15(Suppl):S57-63 REVIEW ARTICLE Revisiting the Role of Anti-angiogenesis Therapy in Metastatic Breast Cancer CH Kwok Department of Oncology, Princess Margaret Hospital, Hong Kong ABSTRACT Angiogenesis is essential for tumour growth and metastasis, and constitutes an important process in the control of cancer progression.
HER2/neu ph2 ADC Therapeutics CD19 ph2 relapsed or refractory DLBCL ADC Therapeutics CD25 ph2 Hodgkin lymphoma AbbVie c-met ph2 NSCLC 6SK BCMA ph2 Multiple myeloma Roche LIV1 Ph1/2 Triple Negative Breast Cancer(TNBC) Daiichi Sankyo HER3 Ph1/2 BMS-986148 BMS mesothelin Ph1/2 solid tumor enapotamab Seattle Genetics AXL Ph1/2 solid tumor mirvetuximab soravtansine trastuzumab duocarmazine trastuzumab Bio-Thera maytansine Solutions anetumab ravtansine tisotumab vedotin Remegen RC48 loncsstuximab tesirine camidanlumab tesirine telisotuzumab vedotin belantamab mafodotin ladiratuzumab vedotin patritumab deruxtecan HER2 positive metastatic breast cancer HER2 positive metastatic breast cancer pancreatic cancer ovarian cancer HER2 positive metastatic breast cancer HER3 positive metastatic breast cancer https://www.biochempeg.com Biochempeg Scientific Inc.
This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the colorectal cancer market, with coverage of multiple settings of the disease including neoadjuvant/adjuvant, first-, second-, third-line KRAS wild-type and mutation-positive, and fourth-line metastatic.
The majority of patients with metastatic breast cancer (MBC) have hormone receptor-positive HER2-negative disease.
Biochempeg https://www.biochempeg.com FDA Approves Sacituzumab Govitecan for Triple-Negative Breast Cancer On April 22, 2020, the FDA has granted an accelerated approval to the antibody-drug conjugate (ADC) sacituzumab govitecan-hziy (Trodelvy, Immunomedics, Inc.) for the treatment of adult patients with metastatic triple-negative breast cancer (TNBC) who have received at least 2 prior therapies for metastatic disease.
박영석(성균관의대), 오상철(고려의대) 14:30-14:55 25min Immunotherapy for MSI-High Metastatic Colorectal Cancer 14:55-15:20 25min Approaches to MSS-Metastatic CRC 15:20-15:30 10min Q&A Cutting Edge of the Treatment of Metastatic Colorectal Cancer 김선영(울산의대) 임유주(서울의대) 김승태(성균관의대) 좌장 :
NKX3.1 NKX3.1 may prove to be a valuable marker to assist in determining prostatic origin in poorly differentiated metastatic carcinomas.
A Rare Case Report Of Coexisting Mutually Exclusive KRAS And BRAF Mutations In A Patient With Metastatic Colon Adenocarcinoma Anusha Vittal MBBS 1, Anup Kasi Loknath Kumar MD, MPH 2 1 Department of Internal Medicine, 2 Division of Medical Oncology, University of Kansas Medical Center, Kansas City, KS Abstract Discussion Background:
NCCN Guidelines Version 3.2015 Table of Contents Melanoma NCCN Melanoma Panel Members Summary of the Guidelines Updates Clinical Presentation and Preliminary Workup (ME-1) Stage 0 (in situ), Stage IA (ME-2) Stage IB, Stage II (ME-3) Stage III (ME-4) Stage III In-Transit (ME-5) Stage IV Metastatic (ME-6) Follow-up (ME-7) Persistent Disease or True Local Scar Recurrence;
10951 (Amendment n2) titled as “Randomized phase II - III study in first line hormonal treatment for metastatic breast cancer with EORTC Exemestane or Tamoxifen in Postmenopausal patients".
The 2nd MBC Summit....................................................................................................................................6 Metastatic Breast Cancer........................................................................................................................
cvfile 0023228 82%
Phase III, Multicenter, Randomized Trial of Maintenance Chemotherapy Versus Observation in Patients With Metastatic Breast Cancer After Achieving Disease Control With Six Cycles of Gemcitabine Plus Paclitaxel As First-Line Chemotherapy:
Xynos (Heraklion) Anal Squamous Cell Cancer Surgical Anatomy of Transverse Colon Liver Metastatic Disease Radiomics Unresectable-to-Resectable Conversion Neo-Adjuvant Treatment for Locally Advanced Disease Increasing Resectability Rates Immunotherapy Management of Synchronous CRC Surgical Treatment:
16α-[18F]Fluoro-17β-estradiol (18F-FES) has proven to be a promising tracer for in vivo imaging studies of the ER status of primary and metastatic breast cancer.
Stanimir -McG 0010- (98-6475-183) A Ran domized, Open-Label, M ulticenter, Phase Ill Study St udy Comparing t he Efficacy and Safety of Gemcitabine and lrenotecan HCI (CPT-11) to t he Gemcita bine Alon e in Patients w ith Locally Advanced or Metastatic Pancreat ic Cancer who Have Not Received Prior Systemic Therapy Pharmacia TERM INATED (Dr.
Medical treatment for advanced and metastatic PCa David Quinn 15.50 – 18.00 Live surgeries 1.
Optimal chemotherapy after curative surgical resection of metastatic colorectal cancer 이명아 (가톨릭의대) 김정호 (서울의대) 40,000원 기타, 업체 참가 50,000원 60,000원 김승태 (성균관의대) 좌장 :
Weston Johnson, a former football player for the University of Wyoming and the current assistant football coach at Sheridan High School has recently been diagnosed with metastatic cancer.
Pretesh Patel, MD UPDATE ON SYSTEMIC THERAPY FOR METASTATIC GASTRIC/GASTROESOPHAGEAL CANCERS Christina Wu, MD Q&A Mihir Shah, MD (Moderator) COFFEE BREAK AND MEET EXHIBITORS SESSION 2 HEPATOBILIARY MALIGNANCIES 10:05-10:20 CHOLANGIOCARCINOMA: